At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 320 enrolled
Drug / intervention
LY3819469 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a)
In Brief
A Phase 2 clinical trial evaluating LY3819469 and Placebo for Lipoprotein Disorder. Completed, enrolled 320 participants across 80 sites in 10 countries.
Detailed Summary
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLipoprotein Disorder
CountriesArgentina, China, Denmark, Germany, Japan, Mexico, Netherlands, Romania, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartOct 2022
Primary CompletionOct 2023
Study CompletionOct 2024
TodayJul 2026
First PostedOct 4, 2022
Enrollment StartOct 20, 2022
Primary CompletionOct 23, 2023
Study CompletionOct 17, 2024
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 3.7 years ago
Interventions
LY3819469drug
Administered SC
Placebodrug
Administered SC